+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Hepatic Fibrosis Biomarkers Market Size, Share & Trends Analysis Report by Product (Blood-based Kits, Saliva-based Kits), by Technology (Immunofiltration Assays, Lateral Flow Assays), by End Use, by Region, and Segment Forecasts, 2025-2033- Product Image
Hepatic Fibrosis Biomarkers Market Size, Share & Trends Analysis Report by Product (Blood-based Kits, Saliva-based Kits), by Technology (Immunofiltration Assays, Lateral Flow Assays), by End Use, by Region, and Segment Forecasts, 2025-2033- Product Image
New

Hepatic Fibrosis Biomarkers Market Size, Share & Trends Analysis Report by Product (Blood-based Kits, Saliva-based Kits), by Technology (Immunofiltration Assays, Lateral Flow Assays), by End Use, by Region, and Segment Forecasts, 2025-2033

  • PDF Icon

    Report

  • 150 Pages
  • August 2025
  • Region: Global
  • Grand View Research
  • ID: 6168232
Description Jump to:
The global hepatic fibrosis biomarkers market size was estimated at USD 423.51 million in 2024 and is projected to reach USD 2.29 billion by 2033, growing at a CAGR of 20.01% from 2025 to 2033. The rising prevalence of NASH, a consequence of obesity, sedentary lifestyles, and metabolic syndrome, has led to a greater focus on hepatic fibrosis biomarkers.

According to the study published in the National Institutes of Diabetes and Digestive and Kidney Diseases, NAFLD affects one-third to two-thirds of individuals with type 2 diabetes. Studies also indicate that over 90% of individuals with extreme obesity and up to 75% of overweight individuals have NAFLD. One of the key drivers propelling the demand for NASH-specific hepatic fibrosis biomarkers is the clinical significance of fibrosis staging. The risks and limitations associated with liver biopsies and non-invasive biomarkers offer a safer and more patient-friendly approach to monitoring hepatic fibrosis progression in NASH patients.

As of the most recent estimates, approximately 3.3% of the global population is living with advanced hepatic fibrosis, with rates rising to around 3.5% when measured using vibration-controlled transient elastography (VCTE). Non-alcoholic fatty liver disease (NAFLD), recently redefined as metabolic dysfunction-associated steatotic liver disease (MASLD), affects about 25% of the world’s population, with prevalence increasing to 38% in certain regions between 2016 and 2019 due to rising obesity and type 2 diabetes rates.

The adoption of tests such as ELF, FIB-4, NAFLD fibrosis score, APRI, and FibroTest/FibroSure, alongside emerging multi-marker panels like IGFBP7/SSc5D/Sema4D, is enabling earlier detection, accurate staging, and reduced reliance on invasive liver biopsies. These advancements, combined with rising screening initiatives, are positioning hepatic fibrosis biomarkers as a central tool in tackling the global liver disease epidemic.

The dynamics of liver fibrosis are specifically targeted by noninvasive biomarkers of liver condition, such as NASH, which offer a novel tool to assess a patient's disease progression. Such indicators for liver illness could be applied to patient risk classification as well as prognostic enrichment of clinical trials aimed at the individuals with the highest risk, improving the likelihood of success. These blood biomarkers are also accurate indicators of the dynamics of liver fibrosis and can be used to gauge the success of a given treatment. Nordic Bioscience NASH specialists can examine a precise panel of liver fibrosis biomarkers, including the biomarker PRO-C3 NASH, which offers insight into the course of the illness.

Global Hepatic Fibrosis Biomarkers Market Report Segmentation

This report forecasts revenue growth and provides an analysis of the latest trends in each of the sub-segments from 2021 to 2033. The analyst has segmented the global hepatic fibrosis biomarkers market report based on product, technology, end use, and region:

Product Outlook (Revenue, USD Million, 2021-2033)

  • Kits and Reagents
  • Assays
  • Services

Technology Outlook (Revenue, USD Million, 2021-2033)

  • Immunoassay
  • Molecular Diagnostics
  • Proteomics/Metabolomics
  • Imaging-based Biomarker Assessment

End Use Outlook (Revenue, USD Million, 2021-2033)

  • Hospitals
  • Diagnostic Laboratories
  • Specialty Clinics
  • Academic & Research Institutes
  • Pharmaceutical & Biotechnology Companies

Regional Outlook (Revenue, USD Million, 2021-2033)

  • North America
  • U.S.
  • Canada
  • Mexico
  • Europe
  • UK
  • Germany
  • France
  • Italy
  • Spain
  • Denmark
  • Sweden
  • Norway
  • Asia-Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Thailand
  • Latin America
  • Brazil
  • Argentina
  • Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait

Why should you buy this report?

  • Comprehensive Market Analysis: Gain detailed insights into the industry across major regions and segments.
  • Competitive Landscape: Explore the market presence of key players.
  • Future Trends: Discover the pivotal trends and drivers shaping the future of the market.
  • Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions.

This report addresses:

  • Market intelligence to enable effective decision-making
  • Market estimates and forecasts from 2018 to 2030
  • Growth opportunities and trend analyses
  • Segmental and regional revenue forecasts for market assessment
  • Competition strategy and market share analysis
  • Product innovation listings for you to stay ahead of the curve
  • COVID-19's impact and how to sustain in these fast-evolving markets

This product will be delivered within 1-3 business days.

Table of Contents

Chapter 1. Hepatic Fibrosis Biomarkers Market: Methodology and Scope
1.1. Market Segmentation and Scope
1.1.1. Segment Definitions
1.1.1.1. Product Segment
1.1.1.2. Technology Segment
1.1.1.3. Sample Product segment
1.1.1.4. End Use Segment
1.2. Regional Scope
1.3. Estimates and Forecast Timeline
1.4. Objectives
1.4.1. Objective - 1
1.4.2. Objective - 2
1.4.3. Objective - 3
1.5. Research Methodology
1.6. Information Procurement
1.6.1. Purchased Database
1.6.2. Internal Database
1.6.3. Secondary Sources
1.6.4. Primary Research
1.7. Information or Data Analysis
1.7.1. Data Analysis Models
1.8. Market Formulation & Validation
1.9. Model Details
1.9.1. Commodity Flow Analysis
1.10. List of Secondary Sources
1.11. List of Abbreviations
Chapter 2. Hepatic Fibrosis Biomarkers Market: Executive Summary
2.1. Market Snapshot
2.2. Product and Technology Snapshot
2.3. End Use Snapshot
2.4. Competitive Landscape Snapshot
Chapter 3. Hepatic Fibrosis Biomarkers Market Variables, Trends, & Scope
3.1. Market Segmentation and Scope
3.2. Market Lineage Outlook
3.2.1. Parent Market Outlook
3.2.2. Related/Ancillary Market Outlook
3.3. Market Dynamics
3.4. Market Drivers Analysis
3.5. Market Restraint Analysis
3.6. Porter’s Five Forces Analysis
3.7. PESTLE Analysis
3.8. Pipeline Analysis
Chapter 4. Hepatic Fibrosis Biomarkers Market: Product Estimates & Trend Analysis
4.1. Hepatic Fibrosis Biomarkers Market: Product Movement Analysis
4.2. Kits and Reagents
4.2.1. Market Estimates and Forecasts, 2021-2033 (USD Million)
4.3. Assays
4.3.1. Market Estimates and Forecasts, 2021-2033 (USD Million)
4.4. Services
4.4.1. Market Estimates and Forecasts, 2021-2033 (USD Million)
Chapter 5. Hepatic Fibrosis Biomarkers Market: Technology Estimates & Trend Analysis
5.1. Hepatic Fibrosis Biomarkers Market: Technology Movement Analysis
5.2. Immunoassays
5.2.1. Market Revenue Estimates and Forecasts, 2021-2033 (USD Million)
5.3. Molecular Diagnostics
5.3.1. Market Revenue Estimates and Forecasts, 2021-2033 (USD Million)
5.4. Proteomics/Metabolomics
5.4.1. Market Revenue Estimates and Forecasts, 2021-2033 (USD Million)
5.5. Imaging-based Biomarker Assessment
5.5.1. Market Revenue Estimates and Forecasts, 2021-2033 (USD Million)
Chapter 6. Hepatic Fibrosis Biomarkers Market: End Use Estimates & Trend Analysis
6.1. Hepatic Fibrosis Biomarkers Market: End Use Movement Analysis
6.2. Hospitals
6.2.1. Market Revenue Estimates and Forecasts, 2021-2033 (USD Million)
6.3. Diagnostics Laboratories
6.3.1. Market Revenue Estimates and Forecasts, 2021-2033 (USD Million)
6.4. Specialty Clinics
6.4.1. Market Revenue Estimates and Forecasts, 2021-2033 (USD Million)
6.5. Academic & Research Institutes
6.5.1. Market Revenue Estimates and Forecasts, 2021-2033 (USD Million)
6.6. Pharmaceutical & Biotechnology Companies
6.6.1. Market Revenue Estimates and Forecasts, 2021-2033 (USD Million)
Chapter 7. Hepatic Fibrosis Biomarkers Market: Regional Business Analysis
7.1. Regional Market Snapshot
7.2. North America
7.2.1. North America Hepatic Fibrosis Biomarkers Market Estimates and Forecast, 2021-2033 (USD Million)
7.2.2. U.S.
7.2.2.1. U.S. Hepatic Fibrosis Biomarkers Market, 2021-2033 (USD Million)
7.2.2.2. Key Country Dynamics
7.2.2.3. Regulatory Framework
7.2.2.4. Reimbursement Scenario
7.2.2.5. Competitive Scenario
7.2.3. Canada
7.2.3.1. Canada Hepatic Fibrosis Biomarkers Market, 2021-2033 (USD Million)
7.2.3.2. Key Country Dynamics
7.2.3.3. Regulatory Framework
7.2.3.4. Reimbursement Scenario
7.2.3.5. Competitive Scenario
7.2.4. Mexico
7.2.4.1. Mexico Hepatic Fibrosis Biomarkers Market, 2021-2033 (USD Million)
7.2.4.2. Key Country Dynamics
7.2.4.3. Regulatory Framework
7.2.4.4. Reimbursement Scenario
7.2.4.5. Competitive Scenario
7.3. Europe
7.3.1. Europe Hepatic Fibrosis Biomarkers Market, 2021-2033 (USD Million)
7.3.2. UK
7.3.2.1. UK Hepatic Fibrosis Biomarkers Market, 2021-2033 (USD Million)
7.3.2.2. Key Country Dynamics
7.3.2.3. Regulatory Framework
7.3.2.4. Reimbursement Scenario
7.3.2.5. Competitive Scenario
7.3.3. Germany
7.3.3.1. Germany Hepatic Fibrosis Biomarkers Market, 2021-2033 (USD Million)
7.3.3.2. Key Country Dynamics
7.3.3.3. Regulatory Framework
7.3.3.4. Reimbursement Scenario
7.3.3.5. Competitive Scenario
7.3.4. Spain
7.3.4.1. Spain Hepatic Fibrosis Biomarkers Market, 2021-2033 (USD Million)
7.3.4.2. Key Country Dynamics
7.3.4.3. Regulatory Framework
7.3.4.4. Reimbursement Scenario
7.3.4.5. Competitive Scenario
7.3.5. France
7.3.5.1. France Hepatic Fibrosis Biomarkers Market, 2021-2033 (USD Million)
7.3.5.2. Key Country Dynamics
7.3.5.3. Regulatory Framework
7.3.5.4. Reimbursement Scenario
7.3.5.5. Competitive Scenario
7.3.6. Italy
7.3.6.1. Italy Hepatic Fibrosis Biomarkers Market, 2021-2033 (USD Million)
7.3.6.2. Key Country Dynamics
7.3.6.3. Regulatory Framework
7.3.6.4. Reimbursement Scenario
7.3.6.5. Competitive Scenario
7.3.7. Denmark
7.3.7.1. Denmark Hepatic Fibrosis Biomarkers Market, 2021-2033 (USD Million)
7.3.7.2. Key Country Dynamics
7.3.7.3. Regulatory Framework
7.3.7.4. Reimbursement Scenario
7.3.7.5. Competitive Scenario
7.3.8. Sweden
7.3.8.1. Sweden Hepatic Fibrosis Biomarkers Market, 2021-2033 (USD Million)
7.3.8.2. Key Country Dynamics
7.3.8.3. Regulatory Framework
7.3.8.4. Reimbursement Scenario
7.3.8.5. Competitive Scenario
7.3.9. Norway
7.3.9.1. Norway Hepatic Fibrosis Biomarkers Market, 2021-2033 (USD Million)
7.3.9.2. Key Country Dynamics
7.3.9.3. Regulatory Framework
7.3.9.4. Reimbursement Scenario
7.3.9.5. Competitive Scenario
7.4. Asia-Pacific
7.4.1. Asia-Pacific Hepatic Fibrosis Biomarkers Market, 2021-2033 (USD Million)
7.4.2. Japan
7.4.2.1. Japan Hepatic Fibrosis Biomarkers Market, 2021-2033 (USD Million)
7.4.2.2. Key Country Dynamics
7.4.2.3. Regulatory Framework
7.4.2.4. Reimbursement Scenario
7.4.2.5. Competitive Scenario
7.4.3. China
7.4.3.1. China Hepatic Fibrosis Biomarkers Market, 2021-2033 (USD Million)
7.4.3.2. Key Country Dynamics
7.4.3.3. Regulatory Framework
7.4.3.4. Reimbursement Scenario
7.4.3.5. Competitive Scenario
7.4.4. India
7.4.4.1. India Hepatic Fibrosis Biomarkers Market, 2021-2033 (USD Million)
7.4.4.2. Key Country Dynamics
7.4.4.3. Regulatory Framework
7.4.4.4. Reimbursement Scenario
7.4.4.5. Competitive Scenario
7.4.5. South Korea
7.4.5.1. South Korea Hepatic Fibrosis Biomarkers Market, 2021-2033 (USD Million)
7.4.5.2. Key Country Dynamics
7.4.5.3. Regulatory Framework
7.4.5.4. Reimbursement Scenario
7.4.5.5. Competitive Scenario
7.4.6. Thailand
7.4.6.1. Thailand Hepatic Fibrosis Biomarkers Market, 2021-2033 (USD Million)
7.4.6.2. Key Country Dynamics
7.4.6.3. Regulatory Framework
7.4.6.4. Reimbursement Scenario
7.4.6.5. Competitive Scenario
7.4.7. Australia
7.4.7.1. Australia Hepatic Fibrosis Biomarkers Market, 2021-2033 (USD Million)
7.4.7.2. Key Country Dynamics
7.4.7.3. Regulatory Framework
7.4.7.4. Reimbursement Scenario
7.4.7.5. Competitive Scenario
7.5. Latin America
7.5.1. Latin America Hepatic Fibrosis Biomarkers Market, 2021-2033 (USD Million)
7.5.2. Brazil
7.5.2.1. Brazil Hepatic Fibrosis Biomarkers Market, 2021-2033 (USD Million)
7.5.2.2. Key Country Dynamics
7.5.2.3. Regulatory Framework
7.5.2.4. Reimbursement Scenario
7.5.2.5. Competitive Scenario
7.5.3. Argentina
7.5.3.1. Argentina Hepatic Fibrosis Biomarkers Market, 2021-2033 (USD Million)
7.5.3.2. Key Country Dynamics
7.5.3.3. Regulatory Framework
7.5.3.4. Reimbursement Scenario
7.5.3.5. Competitive Scenario
7.6. MEA
7.6.1. MEA Hepatic Fibrosis Biomarkers Market, 2021-2033 (USD Million)
7.6.2. South Africa
7.6.2.1. South Africa Hepatic Fibrosis Biomarkers Market, 2021-2033 (USD Million)
7.6.2.2. Key Country Dynamics
7.6.2.3. Regulatory Framework
7.6.2.4. Reimbursement Scenario
7.6.2.5. Competitive Scenario
7.6.3. Saudi Arabia
7.6.3.1. Saudi Arabia Hepatic Fibrosis Biomarkers Market, 2021-2033 (USD Million)
7.6.3.2. Key Country Dynamics
7.6.3.3. Regulatory Framework
7.6.3.4. Reimbursement Scenario
7.6.3.5. Competitive Scenario
7.6.4. UAE
7.6.4.1. UAE Hepatic Fibrosis Biomarkers Market, 2021-2033 (USD Million)
7.6.4.2. Key Country Dynamics
7.6.4.3. Regulatory Framework
7.6.4.4. Reimbursement Scenario
7.6.4.5. Competitive Scenario
7.6.5. Kuwait
7.6.5.1. Kuwait Hepatic Fibrosis Biomarkers Market, 2021-2033 (USD Million)
7.6.5.2. Key Country Dynamics
7.6.5.3. Regulatory Framework
7.6.5.4. Reimbursement Scenario
7.6.5.5. Competitive Scenario
Chapter 8. Competitive Landscape
8.1. Company Categorization
8.2. Strategy Mapping
8.2.1. New Product Launch
8.2.2. Partnerships
8.2.3. Acquisition
8.2.4. Collaboration
8.2.5. Funding
8.3. Key Company Market Share Analysis, 2024
8.4. Company Heat Map Analysis
8.5. Company Profiles
8.5.1. GENFIT
8.5.1.1. Company Overview
8.5.1.2. Financial Performance
8.5.1.3. Product Benchmarking
8.5.1.4. Strategic Initiatives
8.5.2. Prometheus Laboratories
8.5.2.1. Company Overview
8.5.2.2. Financial Performance
8.5.2.3. Product Benchmarking
8.5.2.4. Strategic Initiatives
8.5.3. Siemens Healthineers AG
8.5.3.1. Company Overview
8.5.3.2. Financial Performance
8.5.3.3. Product Benchmarking
8.5.3.4. Strategic Initiatives
8.5.4. BioPredictive
8.5.4.1. Company Overview
8.5.4.2. Financial Performance
8.5.4.3. Product Benchmarking
8.5.4.4. Strategic Initiatives
8.5.5. Quest Diagnostics
8.5.5.1. Company Overview
8.5.5.2. Financial Performance
8.5.5.3. Product Benchmarking
8.5.5.4. Strategic Initiatives
8.5.6. AstraZeneca
8.5.6.1. Company Overview
8.5.6.2. Financial Performance
8.5.6.3. Product Benchmarking
8.5.6.4. Strategic Initiatives
8.5.7. Exalenz Bioscience Ltd (meridian bioscience)
8.5.7.1. Company Overview
8.5.7.2. Financial Performance
8.5.7.3. Product Benchmarking
8.5.7.4. Strategic Initiatives
8.5.8. Labcorp
8.5.8.1. Company Overview
8.5.8.2. Financial Performance
8.5.8.3. Product Benchmarking
8.5.8.4. Strategic Initiatives
8.5.9. Pfizer Inc.
8.5.9.1. Company Overview
8.5.9.2. Financial Performance
8.5.9.3. Product Benchmarking
8.5.9.4. Strategic Initiatives
8.5.10. Bristol-Myers Squibb Company
8.5.10.1. Company Overview
8.5.10.2. Financial Performance
8.5.10.3. Product Benchmarking
8.5.10.4. Strategic Initiatives
List of Tables
Table 1 List of Secondary Sources
Table 2 List of Abbreviation
Table 3 Global Hepatic Fibrosis Biomarkers Market, by Region, 2021-2033 (USD Million)
Table 4 Global Hepatic Fibrosis Biomarkers Market, by Product, 2021-2033 (USD Million)
Table 5 Global Hepatic Fibrosis Biomarkers Market, by Technology, 2021-2033 (USD Million)
Table 6 Global Hepatic Fibrosis Biomarkers Market, by End Use, 2021-2033 (USD Million)
Table 7 North America Hepatic Fibrosis Biomarkers Market, by Country, 2021-2033 (USD Million)
Table 8 North America Hepatic Fibrosis Biomarkers Market, by Product, 2021-2033 (USD Million)
Table 9 North America Hepatic Fibrosis Biomarkers Market, by Technology, 2021-2033 (USD Million)
Table 10 North America Hepatic Fibrosis Biomarkers Market, by End Use, 2021-2033 (USD Million)
Table 11 U.S. Hepatic Fibrosis Biomarkers Market, by Product, 2021-2033 (USD Million)
Table 12 U.S. Hepatic Fibrosis Biomarkers Market, by Technology, 2021-2033 (USD Million)
Table 13 U.S. Hepatic Fibrosis Biomarkers Market, by End Use, 2021-2033 (USD Million)
Table 14 Canada Hepatic Fibrosis Biomarkers Market, by Product, 2021-2033 (USD Million)
Table 15 Canada Hepatic Fibrosis Biomarkers Market, by Technology, 2021-2033 (USD Million)
Table 16 Canada Hepatic Fibrosis Biomarkers Market, by End Use, 2021-2033 (USD Million)
Table 17 Mexico Hepatic Fibrosis Biomarkers Market, by Product, 2021-2033 (USD Million)
Table 18 Mexico Hepatic Fibrosis Biomarkers Market, by Technology, 2021-2033 (USD Million)
Table 19 Mexico Hepatic Fibrosis Biomarkers Market, by End Use, 2021-2033 (USD Million)
Table 20 Europe Hepatic Fibrosis Biomarkers Market, by Country, 2021-2033 (USD Million)
Table 21 Europe Hepatic Fibrosis Biomarkers Market, by Product, 2021-2033 (USD Million)
Table 22 Europe Hepatic Fibrosis Biomarkers Market, by Technology, 2021-2033 (USD Million)
Table 23 Europe Hepatic Fibrosis Biomarkers Market, by End Use, 2021-2033 (USD Million)
Table 24 UK Hepatic Fibrosis Biomarkers Market, by Product, 2021-2033 (USD Million)
Table 25 UK Hepatic Fibrosis Biomarkers Market, by Technology, 2021-2033 (USD Million)
Table 26 UK Hepatic Fibrosis Biomarkers Market, by End Use, 2021-2033 (USD Million)
Table 27 Germany Hepatic Fibrosis Biomarkers Market, by Product, 2021-2033 (USD Million)
Table 28 Germany Hepatic Fibrosis Biomarkers Market, by Technology, 2021-2033 (USD Million)
Table 29 Germany Hepatic Fibrosis Biomarkers Market, by End Use, 2021-2033 (USD Million)
Table 30 France Hepatic Fibrosis Biomarkers Market, by Product, 2021-2033 (USD Million)
Table 31 France Hepatic Fibrosis Biomarkers Market, by Technology, 2021-2033 (USD Million)
Table 32 France Hepatic Fibrosis Biomarkers Market, by End Use, 2021-2033 (USD Million)
Table 33 Italy Hepatic Fibrosis Biomarkers Market, by Product, 2021-2033 (USD Million)
Table 34 Italy Hepatic Fibrosis Biomarkers Market, by Technology, 2021-2033 (USD Million)
Table 35 Italy Hepatic Fibrosis Biomarkers Market, by End Use, 2021-2033 (USD Million)
Table 36 Spain Hepatic Fibrosis Biomarkers Market, by Product, 2021-2033 (USD Million)
Table 37 Spain Hepatic Fibrosis Biomarkers Market, by Technology, 2021-2033 (USD Million)
Table 38 Spain Hepatic Fibrosis Biomarkers Market, by End Use, 2021-2033 (USD Million)
Table 39 Sweden Hepatic Fibrosis Biomarkers Market, by Product, 2021-2033 (USD Million)
Table 40 Sweden Hepatic Fibrosis Biomarkers Market, by Technology, 2021-2033 (USD Million)
Table 41 Sweden Hepatic Fibrosis Biomarkers Market, by End Use, 2021-2033 (USD Million)
Table 42 Norway Hepatic Fibrosis Biomarkers Market, by Product, 2021-2033 (USD Million)
Table 43 Norway Hepatic Fibrosis Biomarkers Market, by Technology, 2021-2033 (USD Million)
Table 44 Norway Hepatic Fibrosis Biomarkers Market, by End Use, 2021-2033 (USD Million)
Table 45 Denmark Hepatic Fibrosis Biomarkers Market, by Product, 2021-2033 (USD Million)
Table 46 Denmark Hepatic Fibrosis Biomarkers Market, by Technology, 2021-2033 (USD Million)
Table 47 Denmark Hepatic Fibrosis Biomarkers Market, by End Use, 2021-2033 (USD Million)
Table 48 Asia-Pacific Hepatic Fibrosis Biomarkers Market, by Country, 2021-2033 (USD Million)
Table 49 Asia-Pacific Hepatic Fibrosis Biomarkers Market, by Product, 2021-2033 (USD Million)
Table 50 Asia-Pacific Hepatic Fibrosis Biomarkers Market, by Technology, 2021-2033 (USD Million)
Table 51 Asia-Pacific Hepatic Fibrosis Biomarkers Market, by End Use, 2021-2033 (USD Million)
Table 52 Japan Hepatic Fibrosis Biomarkers Market, by Product, 2021-2033 (USD Million)
Table 53 Japan Hepatic Fibrosis Biomarkers Market, by Technology, 2021-2033 (USD Million)
Table 54 Japan Hepatic Fibrosis Biomarkers Market, by End Use, 2021-2033 (USD Million)
Table 55 China Hepatic Fibrosis Biomarkers Market, by Product, 2021-2033 (USD Million)
Table 56 China Hepatic Fibrosis Biomarkers Market, by Technology, 2021-2033 (USD Million)
Table 57 China Hepatic Fibrosis Biomarkers Market, by End Use, 2021-2033 (USD Million)
Table 58 India Hepatic Fibrosis Biomarkers Market, by Product, 2021-2033 (USD Million)
Table 59 India Hepatic Fibrosis Biomarkers Market, by Technology, 2021-2033 (USD Million)
Table 60 India Hepatic Fibrosis Biomarkers Market, by End Use, 2021-2033 (USD Million)
Table 61 Australia Hepatic Fibrosis Biomarkers Market, by Product, 2021-2033 (USD Million)
Table 62 Australia Hepatic Fibrosis Biomarkers Market, by Technology, 2021-2033 (USD Million)
Table 63 Australia Hepatic Fibrosis Biomarkers Market, by End Use, 2021-2033 (USD Million)
Table 64 Thailand Hepatic Fibrosis Biomarkers Market, by Product, 2021-2033 (USD Million)
Table 65 Thailand Hepatic Fibrosis Biomarkers Market, by Technology, 2021-2033 (USD Million)
Table 66 Thailand Hepatic Fibrosis Biomarkers Market, by End Use, 2021-2033 (USD Million)
Table 67 South Korea Hepatic Fibrosis Biomarkers Market, by Product, 2021-2033 (USD Million)
Table 68 South Korea Hepatic Fibrosis Biomarkers Market, by Technology, 2021-2033 (USD Million)
Table 69 South Korea Hepatic Fibrosis Biomarkers Market, by End Use, 2021-2033 (USD Million)
Table 70 Latin America Hepatic Fibrosis Biomarkers Market, by Country, 2021-2033 (USD Million)
Table 71 Latin America Hepatic Fibrosis Biomarkers Market, by Product, 2021-2033 (USD Million)
Table 72 Latin America Hepatic Fibrosis Biomarkers Market, by Technology, 2021-2033 (USD Million)
Table 73 Latin America Hepatic Fibrosis Biomarkers Market, by End Use, 2021-2033 (USD Million)
Table 74 Brazil Hepatic Fibrosis Biomarkers Market, by Product, 2021-2033 (USD Million)
Table 75 Brazil Hepatic Fibrosis Biomarkers Market, by Technology, 2021-2033 (USD Million)
Table 76 Brazil Hepatic Fibrosis Biomarkers Market, by End Use, 2021-2033 (USD Million)
Table 77 Argentina Hepatic Fibrosis Biomarkers Market, by Product, 2021-2033 (USD Million)
Table 78 Argentina Hepatic Fibrosis Biomarkers Market, by Technology, 2021-2033 (USD Million)
Table 79 Argentina Hepatic Fibrosis Biomarkers Market, by End Use, 2021-2033 (USD Million)
Table 80 MEA Hepatic Fibrosis Biomarkers Market, by Country, 2021-2033 (USD Million)
Table 81 MEA Hepatic Fibrosis Biomarkers Market, by Product, 2021-2033 (USD Million)
Table 82 MEA Hepatic Fibrosis Biomarkers Market, by Technology, 2021-2033 (USD Million)
Table 83 MEA Hepatic Fibrosis Biomarkers Market, by End Use, 2021-2033 (USD Million)
Table 84 South Africa Hepatic Fibrosis Biomarkers Market, by Product, 2021-2033 (USD Million)
Table 85 South Africa Hepatic Fibrosis Biomarkers Market, by Technology, 2021-2033 (USD Million)
Table 86 South Africa Hepatic Fibrosis Biomarkers Market, by End Use, 2021-2033 (USD Million)
Table 87 Saudi Arabia Hepatic Fibrosis Biomarkers Market, by Product, 2021-2033 (USD Million)
Table 88 Saudi Arabia Hepatic Fibrosis Biomarkers Market, by Technology, 2021-2033 (USD Million)
Table 89 Saudi Arabia Hepatic Fibrosis Biomarkers Market, by End Use, 2021-2033 (USD Million)
Table 90 UAE Hepatic Fibrosis Biomarkers Market, by Product, 2021-2033 (USD Million)
Table 91 UAE Hepatic Fibrosis Biomarkers Market, by Technology, 2021-2033 (USD Million)
Table 92 UAE Hepatic Fibrosis Biomarkers Market, by End Use, 2021-2033 (USD Million)
Table 93 Kuwait Hepatic Fibrosis Biomarkers Market, by Product, 2021-2033 (USD Million)
Table 94 Kuwait Hepatic Fibrosis Biomarkers Market, by Technology, 2021-2033 (USD Million)
Table 95 Kuwait Hepatic Fibrosis Biomarkers Market, by End Use, 32021 - 2033 (USD Million)
List of Figures
Figure 1 Market research process
Figure 2 Information procurement
Figure 3 Market summary
Figure 4 Market segmentation & scope
Figure 5 Market size and growth prospects
Figure 6 Global Hepatic fibrosis biomarkers market- Key market driver analysis
Figure 7 Global Hepatic fibrosis biomarkers market - Key market restraint analysis
Figure 8 Penetration & growth prospect mapping
Figure 9 Global Hepatic fibrosis biomarkers market - Porter’s analysis
Figure 10 Global Hepatic fibrosis biomarkers market - PESTEL analysis
Figure 11 Global Hepatic fibrosis biomarkers market Product outlook key takeaways
Figure 12 Global Hepatic fibrosis biomarkers market: Product movement analysis
Figure 13 Kits and reagents market estimates, 2021-2033 (USD Million)
Figure 14 Reagents market estimates, 2021-2033 (USD Million)
Figure 15 Services market estimates, 2021-2033 (USD Million)
Figure 16 Global Hepatic fibrosis biomarkers market technology outlook key takeaways
Figure 17 Global Hepatic fibrosis biomarkers market: technology movement analysis
Figure 18 Immunoassays market estimates, 2021-2033 (USD Million)
Figure 19 Molecular diagnostics market estimates, 2021-2033 (USD Million)
Figure 20 Proteomics/metabolomics market estimates, 2021-2033 (USD Million)
Figure 21 Imaging-based biomarker assessment market estimates, 2021-2033 (USD Million)
Figure 22 Global Hepatic fibrosis biomarkers market end use outlook key takeaways
Figure 23 Global Hepatic fibrosis biomarkers market: end use movement analysis
Figure 24 Retail and online pharmacies market estimates, 2021-2033 (USD Million)
Figure 25 Hospitals and diagnostics laboratories market estimates, 2021-2033 (USD Million)
Figure 26 NGO/Community-based distribution market estimates, 2021-2033 (USD Million)
Figure 27 Regional marketplace: Key takeaways
Figure 28 Global Hepatic Fibrosis Biomarkers market: Regional movement analysis
Figure 29 North America Hepatic Fibrosis Biomarkers market, 2021-2033 (USD Million)
Figure 30 U.S. Hepatic fibrosis biomarkers market, 2021-2033 (USD Million)
Figure 31 Canada Hepatic fibrosis biomarkers market, 2021-2033 (USD Million)
Figure 32 Mexico Hepatic fibrosis biomarkers market, 2021-2033 (USD Million)
Figure 33 Europe Hepatic fibrosis biomarkers market, 2021-2033 (USD Million)
Figure 34 UK Hepatic fibrosis biomarkers market, 2021-2033 (USD Million)
Figure 35 Germany Hepatic fibrosis biomarkers market, 2021-2033 (USD Million)
Figure 36 France Hepatic fibrosis biomarkers market, 2021-2033 (USD Million)
Figure 37 Spain Hepatic fibrosis biomarkers market, 2021-2033 (USD Million)
Figure 38 Italy Hepatic fibrosis biomarkers market, 2021-2033 (USD Million)
Figure 39 Denmark Hepatic fibrosis biomarkers market, 2021-2033 (USD Million)
Figure 40 Sweden Hepatic fibrosis biomarkers market, 2021-2033 (USD Million)
Figure 41 Norway Hepatic fibrosis biomarkers market, 2021-2033 (USD Million)
Figure 42 Asia-Pacific Hepatic fibrosis biomarkers market, 2021-2033 (USD Million)
Figure 43 Japan Hepatic fibrosis biomarkers market, 2021-2033 (USD Million)
Figure 44 China Hepatic fibrosis biomarkers market, 2021-2033 (USD Million)
Figure 45 India Hepatic fibrosis biomarkers market, 2021-2033 (USD Million)
Figure 46 South Korea Hepatic fibrosis biomarkers market, 2021-2033 (USD Million)
Figure 47 Australia Hepatic fibrosis biomarkers market, 2021-2033 (USD Million)
Figure 48 Thailand Hepatic fibrosis biomarkers market, 2021-2033 (USD Million)
Figure 49 Latin America Hepatic fibrosis biomarkers market, 2021-2033 (USD Million)
Figure 50 Brazil Hepatic fibrosis biomarkers market, 2021-2033 (USD Million)
Figure 51 Argentina Hepatic fibrosis biomarkers market, 2021-2033 (USD Million)
Figure 52 MEA Hepatic fibrosis biomarkers market, 2021-2033 (USD Million)
Figure 53 South Africa Hepatic fibrosis biomarkers market, 2021-2033 (USD Million)
Figure 54 Saudi Arabia Hepatic fibrosis biomarkers market, 2021-2033 (USD Million)
Figure 55 UAE Hepatic fibrosis biomarkers market, 2021-2033 (USD Million)
Figure 56 Kuwait Hepatic fibrosis biomarkers market, 2021-2033 (USD Million)
Figure 57 Strategy framework

Companies Mentioned

The major companies profiled in this Hepatic Fibrosis Biomarkers market report include:
  • GENFIT
  • Prometheus Laboratories
  • Siemens Healthineers AG
  • BioPredictive
  • Quest Diagnostics
  • AstraZeneca
  • Exalenz Bioscience Ltd (Meridian Bioscience)
  • Labcorp
  • Pfizer Inc.
  • Bristol-Myers Squibb Company

Table Information

Report AttributeDetails
No. of Pages150
PublishedAugust 2025
Forecast Period2024 - 2033
Estimated Market Value ( USD ) in 2024 $ 423.51 Million
Forecasted Market Value ( USD ) by 2033 $ 2290 Million
Compound Annual Growth Rate20.0%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

U.S. Non-alcoholic Steatohepatitis Biomarkers Market Size, Share & Trends Analysis Report by Type (Serum, Hepatic Fibrosis, Apoptosis), End-use (Hospitals, Diagnostic Labs), and Segment Forecasts, 2024-2030 - Product Image

U.S. Non-alcoholic Steatohepatitis Biomarkers Market Size, Share & Trends Analysis Report by Type (Serum, Hepatic Fibrosis, Apoptosis), End-use (Hospitals, Diagnostic Labs), and Segment Forecasts, 2024-2030

  • Report
  • 70 Pages
  • United States
From
Non-Alcoholic Steatohepatitis Biomarkers Market Report 2025 - Product Image

Non-Alcoholic Steatohepatitis Biomarkers Market Report 2025

  • Report
  • 200 Pages
  • Global
From
Non-alcoholic Steatohepatitis Biomarkers Market Size, Share & Trends Analysis Report by Type (Serum Biomarkers, Hepatic Fibrosis Biomarkers), End Use (Pharma & CRO Industry, Hospitals), Region, with Growth Forecasts, 2025-2030 - Product Image

Non-alcoholic Steatohepatitis Biomarkers Market Size, Share & Trends Analysis Report by Type (Serum Biomarkers, Hepatic Fibrosis Biomarkers), End Use (Pharma & CRO Industry, Hospitals), Region, with Growth Forecasts, 2025-2030

  • Report
  • 120 Pages
  • Global
From
Non-alcoholic Steatohepatitis Biomarkers Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2025-2034 - Product Image

Non-alcoholic Steatohepatitis Biomarkers Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2025-2034

  • Report
  • 120 Pages
  • Global
From
Non-alcoholic Steatohepatitis Biomarkers Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F - Product Image

Non-alcoholic Steatohepatitis Biomarkers Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F

  • Report
  • 183 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.